

FORM PTO-1449 (modified)		Atty. Dkt. No. 037003-0280609				
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: GRILLO-LOPEZ				
		Appln. No.: 09/840,872				
		Filing Date: April 25, 2001				
		Examiner: Gary B. Nickol	Group Art Unit: 1642			
Date: January 12, 2006		Page 1 of 1				
<b>U.S. PATENT DOCUMENTS</b>						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
<b>FOREIGN PATENT DOCUMENTS</b>				English Abstract	Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		
	HR					
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					
<b>OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)</b>						
	OR	Anolik et al., "The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus," <i>Arthritis Rheum.</i> , 2003, 48:455-459.				
	PR	Cartron et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene," <i>Blood</i> , 2002, 99(3): 754-758.				
	QR	Glynes et al., "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets," <i>Nature Medicine</i> , 2000, 6(4): 443-446.				
	RR	Frlese et al., "The innate immune response in the central nervous system and its role in glioma immune surveillance," <i>Onkologie</i> , 2004, 27(5):487-491.				
	SR	Rubenstein et al., "Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment," <i>Blood</i> , 2003, 101(2): 466-468.				
	TR	Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies," <i>Blood</i> , 1998, 91(5): 1644-1652.				
	UR	Shan et al., "Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells," <i>Cancer Immunol. Immunother.</i> , 2000, 48(12): 673-683 (abstract only).				
	VR	Treon et al., "Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia," <i>J. Clin. Oncol.</i> , 2005, 23(3): 474-481.				
Examiner		Date Considered:				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						